Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS:GTSIF) CEO Philip Young presents at Proactive's One2One virtual investor forum.
The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other indications. With five provisional patents, a pre-clinical study underway and a drug delivery device in engineering development, Lobe is quickly making a name for itself in the world of psychedelics.